Thus, our data imply that MAIR‐II activates TLR9‐mediated signalling in macrophages, hence amplifying the pro‐inflammatory response and worsening adverse cardiac outcome after MI (Figure S7). The gene discussed is TLR9; the disease is myocardial infarction.